Overview
Zacks Rank #5 (Strong Sell) stock BioNTech (BNTX) is a German biotech firm that develops and commercializes immunotherapies and innovative cancer treatments based on individualized therapies and precision medicine. The company was founded in 2008 and is based in Mainz, Germany.
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines. The vaccine, called the Pfizer-BioNTech COVID-19 vaccine, has been authorized for emergency use in numerous countries around the world.
Fundamental View
The COVID-19 pandemic was a windfall opportunity for BioNTech and other mRNA vaccine manufacturers. In the heat of the pandemic, BNTX’s EPS grew from zero to nearly $16 per share.
Image Source: Zacks Investment Research
The stock reacted accordingly, rising from $12 to over $400 a share in just months. However, unfortunately for BNTX investors, equities tend to be forward-looking devices rather than backward looking mechanisms. From that perspective, the picture is less rosy. This year, Zacks Consensus Analyst Estimates suggest that BNTX’s earnings will dive 70% year-over-year.
Image Source: Zacks Investment Research
What’s worse is that recent revisions are moving in the wrong direction. Over the past 90 days, Zacks Consensus Analyst Estimates have dropped precipitously.
Image Source: Zacks Investment Research
Technical View
Sometimes, its important to focus on how a stock reacts to earnings, rather than the earnings themselves. Over the past two quarters, BNTX has beat consensus analyst estimates. However, shares are lagging and trading near multi-year lows.
Image Source: Zacks Investment Research
Relatively speaking, BNTX is -25% over the past twelve months while the S&P 500 is only -14%.
Bottom Line
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging. All else being equal, expect BNTX shares to underperform over the next year.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Pfizer Inc. (PFE) : Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
